The COVID-19 Physician Dilemma

 

To escalate or not to escalate level of care?

Some infections resolve quickly, while others lead to severe immune dysregulation, respiratory failure and death. Distinguishing between the two is challenging.

Now CE Marked!
Read the full press release HERE!

GettyImages-1214233757.jpg

Covid-19: A global snapshot

COVID-19: a global snapshot

1 in 5 

patients experience life threatening disease

1

1.png

*Numbers as of May 2021

8% 

Re-admission 

2

~20% 

Potential over admission 

3

4

$35K

Average cost per non-ICU patient

Conventional tests are important, but insufficient
to aid in effective patient management:

Conventional tests are important, but insufficient
to aid in effective patient management:

Conventional tests are important,
but insufficient to aid in effective
patient management:

icon_.png

Inaccurate risk stratification

icon_2.png

Fail to alert prior to organ damage

Uncertainty regarding results interpretation

icon_4.png

Prolonged turnaround time

icon_3.png

Unable to capture 

disease complexity

icon_5.png

Three Biomarkers + Machine Learning = MeMed COVID-19 Severity

TM

MeMed COVID-19 Severity builds on an extensive body of evidence supporting the role of viral-induced TRAIL and IP-10 and inflammatory CRP proteins in severe SARS-CoV-2 infection.

5-7

5

From a small serum sample, MeMed COVID-19 Severity computationally integrates the levels of these three host immune proteins into a simple score indicating the likelihood of patient deterioration.

image 4.png
shutterstock_740523562 white [Converted]_2_.png
shutterstock_1517438624_edit_.jpg

MeMed COVID-19 Severity - 

Predictive & Actionable 

3

• Early indication of deterioration

• Predictive of further disease progression vs. recovery

 

• Ease of use: single serum sample per test

• 15 minutes from sample to result

• Easy to interpret results

Actionable

Predictive

MeMed

COVID-19 Severity

Performance

TM 

image 10.png

*Validation study results, data not published

icon_6.png
icon_62.png

MeMed COVID-19 Severity signature compares favorably with other biomarkers

3

Comparison of area under ROC curve (AUC)

image 9.png

*IMV: Intubation with mechanical ventilation

MeMed Key  runs

the MeMed COVID-19 Severity  test in just 15 minutes, where and when it actually matters.

® 

MeMed Key is a cutting edge, compact immunoassay platform that makes it possible to conduct highly sensitive, multiplexed protein measurements that previously could only be done on expensive central lab equipment.

MeMed BV, MeMed Key & MeMed COVID-19 Severity are CE Marked.

machine_2_.png
logo_memed_key_.png

MeMed BV, MeMed Key and MeMed COVID-19 Severity are not cleared by the FDA for any indication.


MeMed BV, MeMed Key and MeMed COVID-19 Severity are currently not available for sale in the US.

  1. Wu, Z. & McGoogan, J. M. "Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention." JAMA 323, 1239 (2020).

  2. Kilaru, Austin S., et al. "Return hospital admissions among 1419 Covid‐19 patients discharged from five US emergency departments." Academic Emergency Medicine 27.10 (2020): 1039-1042.

  3. Samuel Mastboim, Niv S., et al. "An immune-protein signature combining TRAIL, IP-10, and CRP for accurate prediction of severe COVID-19 outcome." MedRxiv (2021).

  4. https://www.bcbs.com/coronavirus-updates/stories/infographic-covid-19-patients-high-risk-conditions-3x-more-likely-need-the-icu

  5. Ivanisenko, Nikita V., et al. "The role of death domain proteins in host response upon SARS-CoV-2 infection: modulation of programmed cell death and translational applications." Cell death discovery 6.1 (2020): 1-10.

  6. Osuchowski, Marcin F., et al. "The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity." The Lancet Respiratory Medicine (2021).

  7. Guan, Wei-jie, et al. "Clinical characteristics of coronavirus disease 2019 in China." New England journal of medicine 382.18 (2020): 1708-1720.

Contact us for more information about our COVID-19 Severity product

contact us.jpg
arrow&v
arrow&v